Glaxosmithkline Pharmaceuticals Ltd

Glaxosmi. Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Glaxosmithkline Pharmaceuticals Ltd

₹ 2,276 -2.16%
20 Dec - close price
gsk-india.com BSE: 500660 NSE: GLAXO
About

GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)

Key Points

Leading Global Health care company[1] GlaxoSmithKline Pharmaceutical is a part of GlaxoSmithKline plc (GSK), a British multinational pharmaceutical company headquartered in London. GSK underwent a merger in 2000 of Glaxo Wellcome and SmithKline Beecham, and is the world’s sixth-largest pharmaceutical company.

Website BSE NSE
  • Market Cap ₹ 38,556 Cr.
  • Current Price ₹ 2,276
  • High / Low ₹ 3,088 / 1,746
  • Stock P/E 48.4
  • Book Value ₹ 98.8
  • Dividend Yield 1.41 %
  • ROCE 50.7 %
  • ROE 36.8 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 48.0%
  • Company has been maintaining a healthy dividend payout of 90.7%

Cons

  • Stock is trading at 23.0 times its book value
  • The company has delivered a poor sales growth of 1.72% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational

Part of Nifty Midcap150 Momentum 50 Nifty MidSmall Healthcare Nifty Midcap150 Quality 50 BSE Quality Index Nifty Total Market

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
916 808 792 729 906 799 782 738 953 805 911 811 1,000
662 611 618 582 649 571 615 597 667 587 656 582 681
Operating Profit 254 197 173 148 257 228 167 141 287 218 255 229 319
OPM % 28% 24% 22% 20% 28% 29% 21% 19% 30% 27% 28% 28% 32%
30 5 1,322 31 22 12 38 54 28 -135 32 36 37
Interest 0 1 0 1 0 0 1 0 0 0 1 0 0
Depreciation 17 18 15 16 16 16 17 16 18 17 18 16 17
Profit before tax 266 183 1,480 162 262 224 187 179 297 65 269 248 339
Tax % 24% 18% 18% 27% 26% 27% 30% 27% 27% 30% 28% 27% 27%
203 150 1,218 119 194 164 131 131 216 45 193 182 249
EPS in Rs 11.96 8.83 71.89 7.01 11.43 9.68 7.76 7.71 12.72 2.69 11.40 10.72 14.68
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Dec 2012 Dec 2013 Mar 2015 15m Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
2,626 2,546 3,288 2,826 2,903 2,872 3,129 3,225 2,920 3,218 3,216 3,407 3,527
1,811 2,024 2,660 2,349 2,482 2,361 2,522 2,566 2,323 2,462 2,417 2,507 2,506
Operating Profit 815 522 627 477 421 511 606 658 598 756 799 901 1,021
OPM % 31% 20% 19% 17% 14% 18% 19% 20% 20% 23% 25% 26% 29%
49 227 147 125 118 69 106 -247 8 1,402 104 -20 -30
Interest -0 0 0 0 0 0 1 6 4 2 2 2 2
Depreciation 18 20 25 25 27 38 49 83 79 68 66 70 68
Profit before tax 847 729 749 576 511 542 664 322 524 2,087 835 809 921
Tax % 32% 31% 37% 35% 34% 35% 36% 66% 32% 19% 27% 28%
577 502 472 375 337 352 425 110 358 1,691 608 585 669
EPS in Rs 34.08 29.63 27.84 22.11 19.88 20.78 25.11 6.50 21.11 99.79 35.88 34.51 39.49
Dividend Payout % 73% 84% 112% 113% 75% 84% 80% 616% 142% 90% 89% 93%
Compounded Sales Growth
10 Years: 3%
5 Years: 2%
3 Years: 5%
TTM: 8%
Compounded Profit Growth
10 Years: 3%
5 Years: 9%
3 Years: 11%
TTM: 26%
Stock Price CAGR
10 Years: 4%
5 Years: 7%
3 Years: 9%
1 Year: 30%
Return on Equity
10 Years: 28%
5 Years: 37%
3 Years: 48%
Last Year: 37%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Dec 2012 Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 85 85 85 85 85 85 169 169 169 169 169 169 169
Reserves 1,925 1,932 1,767 2,120 1,944 1,995 1,973 1,671 1,328 2,508 1,584 1,615 1,505
5 4 3 2 2 1 1 0 35 20 16 19 15
1,075 1,129 1,382 864 991 1,884 1,766 1,291 1,565 1,925 1,559 1,745 2,041
Total Liabilities 3,090 3,150 3,236 3,071 3,021 3,965 3,909 3,132 3,097 4,623 3,328 3,548 3,730
89 100 123 204 258 325 432 758 387 331 330 321 296
CWIP 44 62 115 268 605 923 1,003 120 13 30 20 14 21
Investments 103 58 48 54 48 48 25 24 24 390 543 838 1,025
2,854 2,930 2,950 2,545 2,110 2,670 2,450 2,229 2,672 3,871 2,435 2,375 2,388
Total Assets 3,090 3,150 3,236 3,071 3,021 3,965 3,909 3,132 3,097 4,623 3,328 3,548 3,730

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Dec 2012 Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
294 267 341 138 232 475 411 491 595 820 488 579
-93 198 178 499 303 -107 -154 -63 408 -420 805 15
-437 -490 -497 -638 -511 -307 -358 -428 -696 -524 -1,544 -562
Net Cash Flow -236 -25 22 -1 25 61 -102 0 307 -124 -251 32

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Dec 2012 Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 16 14 11 16 21 19 14 11 27 23 22 24
Inventory Days 94 108 89 155 111 147 131 135 153 144 128 146
Days Payable 78 88 74 96 72 148 109 99 131 156 122 174
Cash Conversion Cycle 32 34 26 75 61 18 37 47 49 11 27 -4
Working Capital Days -43 -46 -49 25 6 -91 -72 -35 -36 -95 -58 -65
ROCE % 50% 35% 41% 28% 22% 26% 31% 33% 37% 36% 36% 51%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00%
2.04% 2.18% 2.16% 2.17% 2.28% 2.28% 2.41% 2.50% 2.93% 3.48% 4.02% 4.36%
10.73% 10.73% 10.65% 10.54% 10.29% 10.31% 10.25% 10.01% 8.64% 7.90% 7.51% 7.34%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00%
12.23% 12.09% 12.19% 12.29% 12.43% 12.43% 12.35% 12.48% 13.42% 13.62% 13.48% 13.30%
No. of Shareholders 1,23,4801,10,1411,12,9641,16,6511,20,1271,20,4151,19,0321,15,2681,14,6631,18,9941,18,5151,19,228

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls